Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with
or without hypofractionated radiation therapy before surgery works in patients with
pancreatic cancer that can be removed by surgery. Drugs used in combination chemotherapy,
such as oxaliplatin, leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Hypofractionated radiation therapy
delivers higher doses of radiation therapy over a shorter period of time and may kill more
tumor cells and have fewer side effects. It is not yet known if combination chemotherapy is
more effective with or without hypofractionated radiation therapy before surgery in treating
patients with pancreatic cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.